Investment Thesis
Erasca is a pre-revenue biopharmaceutical company with severe operating losses of $187.9M and negative free cash flow of $27.4M, indicating an estimated 1-2 year cash runway at current burn rates. While the balance sheet shows strong equity positioning and zero debt, the absence of revenue and unsustainable operating burn present fundamental challenges requiring successful clinical advancement or near-term capital raises to avoid dilution or restructuring.
Strengths
- Strong balance sheet with $393.5M stockholders' equity and zero long-term debt
- Excellent liquidity ratios (9.52x current ratio) providing runway for operations
- Improving diluted EPS trend (+36.2% YoY) indicating marginal operational efficiency gains
Risks
- Pre-revenue stage with no commercial product sales generating cash
- Negative operating cash flow of $27.4M per quarter with limited cash reserves ($47.3M) implying 1-2 year runway
- Substantial operating losses ($187.9M) and negative profitability metrics (ROE -46.6%, ROA -39.8%) with no clear path to profitability without significant clinical/commercial milestones
Key Metrics to Watch
- Quarterly cash burn rate and remaining cash runway to next financing event
- Clinical trial progress updates and regulatory pathway advancement
- Insider buying/selling patterns and capital structure changes via equity or debt financing
Financial Metrics
Revenue
N/A
Net Income
-183.4M
EPS (Diluted)
$-0.60
Free Cash Flow
-27.4M
Total Assets
461.2M
Cash
47.3M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-46.6%
ROA
-39.8%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
9.52x
Quick Ratio
9.52x
Debt/Equity
0.00x
Debt/Assets
14.7%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-14T08:16:36.773289 |
Data as of: 2026-03-31 |
Powered by Claude AI